United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

United Therapeutics announced FDA acceptance of its NDA for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). The Phase III ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk by 55% versus placebo and improved secondary endpoints. If approved in June 2027, it would be the first once-daily oral prostacyclin for PAH, complementing UTHR's existing PAH portfolio.

Music Beats Cancer Launches “Thumbs Up for a Cure” to Support the Next Generation of Childhood Cancer Treatments

Music Beats Cancer, a nonprofit supporting cancer-fighting biotechnologies, will host its inaugural 'Thumbs Up for a Cure' event on September 5 at LongHouse Reserve in East Hampton. The event brings together families, biotech innovators, philanthropists, and artists to advance childhood cancer treatments. A unique Kids Q&A will feature children evaluating promising technologies from biotech companies developing treatments for difficult-to-treat pediatric cancers including DIPG.

United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027